Dear Health Care Professionals, NCCN has encountered unique issues related to caring for cancer patients in the current COVID-19 pandemic and has realized that their current standard-of-care NCCN Guidelines, do not adequately address some of these issues, such as the limited blood supply, possible impact on those with active infection, and measures that might shorten or prevent hospitalization. These issues may wax and wane, and may require continuous communication with local Blood Bank directors to optimize treatment.
Contributing institutions for this Short-Term Recommendations Specific to Issues with COVID-19 (SARS-CoV-2):
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Dana Farber/Brigham and Women’s Cancer Institute | Massachusetts General Hospital Cancer Center, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Cen
متعاقب انجام شيمي درماني در كودكان مبتلا به سرطان PD-Grastim و Neupogen مقايسه اثر بخشي و عوارض مقايسه كارآيي و عوارض جانبي فيلگراستيم با پيدي گراستيم در پيشگيري از نوتروپني در بيماران نوروبلاستوم تحت شيمي درماني
PDferon® – Successful interferon desensitization in a patient with PDferon® – Preliminary Report of Interferon α2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C PDferon® – Interferon –alpha 2b (PDferon B®) in Treatment of HBeAgnegative PDferon® – Efficacy and safety of Interferon-alpha (PDferon B®)